This is the final submission of the collaborative R01 MH094421 Psychiatric GWAS Consortium: Genomic Follow-Up Next-Gen Sequencing &Genotyping. The overall goal of this application is ambitious:
we aim to generate a trustworthy, high-confidence """"""""maps"""""""" of the genetic architecture of centrally important psychiatric diseases. Such maps consist of systematic and comprehensive evaluation of the allelic spectrum for these disorders including rare exonic, common SNP, and copy number variation. The feasibility of our aims is supported by the track record of the first iteration of the Psychiatric GWAS Consortium (""""""""PGC1"""""""") where we united nearly all major groups in the field into a harmonious and functional entity and completed our initial aims to a high scientific standard. Psychiatric diseases are compelling targets for intensive research: they are mostly idiopathic, first-rank public health problems, and cause enormous morbidity, mortality, and personal/societal cost. Consistent with the NIH mission, our goal is to elucidate fundamental knowledge of these diseases. In this """"""""PGC2"""""""" application, we propose to capitalize on prior NIH investments and on the success of PGC1 for the next logical set of aims. The PGC2 aims are """"""""large-scale"""""""" (largest sample sizes ever in the field) and """"""""comprehensive"""""""" (via the careful application of multiple genomic-scale technologies). Our focus is comprehensive in other senses - the PGC encompasses nearly the entire field, and we aim to elucidate the allelic spectrum of these disorders by integrating empirical data for all readily measurable types of genetic variation of etiological relevance (common SNP, rare exonic, and rare and common copy number variation - what we term the """"""""map""""""""). There are three analytic aims - systematically to assess copy number variation, to create a pipeline for the analysis of exome data (and eventually whole-genome data), and to investigate genetic associations that span traditional disease boundaries. Finally, we propose to develop the """"""""PsychChip"""""""" a custom 20,000 probe array targeting common SNP, exonic, and CNVs that would then be used to genotype 115,082 subjects. The PGC2 impact is potentially very large - a fundamental understanding of the genetics of these diseases would be a major milestone in psychiatry and in biomedicine.

Public Health Relevance

Psychiatric disorders cause enormous human suffering and cost to society. Our goal is rapidly to learn more about the genetics of some of these disorders. We propose to do this via the largest consortium ever constructed in the field, and by the use of several genetic technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01MH094421-02S1
Application #
8664075
Study Section
Special Emphasis Panel (ZRG1-PSE-M (03))
Program Officer
Lehner, Thomas
Project Start
2012-05-10
Project End
2016-03-31
Budget Start
2013-06-15
Budget End
2014-03-31
Support Year
2
Fiscal Year
2013
Total Cost
$97,202
Indirect Cost
$33,253
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Direk, Nese; Williams, Stephanie; Smith, Jennifer A et al. (2017) An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biol Psychiatry 82:322-329
Bigdeli, T B; Ripke, S; Peterson, R E et al. (2017) Genetic effects influencing risk for major depressive disorder in China and Europe. Transl Psychiatry 7:e1074
Marshall, Christian R (see original citation for additional authors) (2017) Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27-35
Pers, Tune H; Timshel, Pascal; Ripke, Stephan et al. (2016) Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes. Hum Mol Genet 25:1247-54
Bigdeli, Tim B; Ripke, Stephan; Bacanu, Silviu-Alin et al. (2016) Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness. Am J Med Genet B Neuropsychiatr Genet 171B:276-89
Edwards, Alexis C; Bacanu, Silviu-Alin; Bigdeli, Tim B et al. (2016) Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res 176:136-140
Lek, Monkol; Karczewski, Konrad J; Minikel, Eric V et al. (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285-91
Sumner, J A; Duncan, L; Ratanatharathorn, A et al. (2016) PTSD has shared polygenic contributions with bipolar disorder and schizophrenia in women. Psychol Med 46:669-71
Franke, Barbara; Stein, Jason L; Ripke, Stephan et al. (2016) Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nat Neurosci 19:420-431
Agrawal, Arpana; Edenberg, Howard J; Gelernter, Joel (2016) Meta-Analyses of Genome-Wide Association Data Hold New Promise for Addiction Genetics. J Stud Alcohol Drugs 77:676-80

Showing the most recent 10 out of 30 publications